NasdaqGS:ONCBiotechs
BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies
BeiGene (NasdaqGS:ONC) recently announced comprehensive analyses from clinical trials at EHA2025, focusing on hematological malignancies, reflecting its commitment to advancing treatment options. However, the company’s share price declined by 2.46% over the last quarter. Despite the unveiling of promising clinical data and revenue growth, these developments seem to have countered broader market trends, where major indices like the S&P 500 and Nasdaq Composite showed gains. BeiGene's improved...